DOSAGE REGIMES FOR ANTI-CD73 AND ANTI-ENTPD2 ANTIBODIES AND USES THEREOF

• Main Authors: GONZALEZ-MAFFE, Juan, OTERO, Javier Alberto, NARDI, Lisa, ZHAI, Tingting, SUBRAMANIAN, Kulandayan Kasi, PARIKH, Nehal, ISAACS, Randi Ellen, KIM, Jaeyeon, ROY, Michael John
• Format: Patent
• Language: English; French
• Published: 04.08.2022
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention generally relates to dosage regimes of anti-Cluster of Differentiation 73 (CD73) antibodies and/or anti-ectoenzyme ectonucleoside triphosphate diphosphohydrolase 2 (ENTPD2) antibodies, used in methods of treatment of cancer in a subject, as well as dosage regimes of anti-CD73 antibodies for use in treating cancer. The invention further generally relates to dosage regimes of combinations of agents, such as combinations comprising anti-CD73 antibodies and/or anti-ENTPD2 antibodies and at least one or more of a PD-1 inhibitor, and an adenosine A2AR antagonist. L'invention concerne de manière générale des régimes posologiques d'anticorps anti-grappe de différenciation 73 (CD73) et/ou d'anticorps anti-ectoenzyme ectonucléoside triphosphate diphosphohydrolase 2 (ENTPD2), utilisés dans des méthodes de traitement du cancer chez un sujet, ainsi que des régimes posologiques d'anticorps anti-CD73 à utiliser dans le traitement du cancer. L'invention concerne en outre de manière générale des régimes posologiques de combinaisons d'agents, telles que des combinaisons comprenant des anticorps anti-CD73 et/ou des anticorps anti-ENTPD2 et un inhibiteur de PD-1 et/ou un antagoniste d'adénosine A2AR.